Wow Michelle... this is exciting news! I am so grateful to those who participate in these trials to further the research that has such potential to help our community.

Gee that is one small sample size for AS so far, lol, I hope they'll be able to recruit a few more ASers ... I'd try not to get your hopes up too high though, as most often these trials are blinded, meaning that even your doctor won't know whether you're getting the placebo or not. Errr, but maybe that's not the case for phase II trials???

Yay - it will be so interesting to read your updates and I'll be keeping my fingers crossed that this new med will work wonderfully for you! I heard they've been working furiously on pill versions of these meds and if they have the same positive effects they'll be such a blessing.

So cool that this one targets IL23 + TNFa.
from Celdene.com:
"Apremilast is a member of a proprietary pipeline of novel small molecules with anti-inflammatory activities that impedes the production of multiple pro-inflammatory mediators by inhibiting PDE4 resulting in reductions in TNF-alpha as well as interleukin-2 (IL-2), IL-17 and IL23, interferon-gamma, leukotrienes, and nitric oxide synthase. Apremilast is our lead investigational drug in this class of anti-inflammatory compounds. Based on promising results from proof-of-mechanism and clinical studies, Celgene is accelerating clinical and regulatory strategies for apremilast in psoriasis and psoriatic arthritis, as well as embarking on exploratory clinical trials in rheumatoid arthritis and additional rheumatic, dermatologic and inflammatory diseases to determine the potential of apremilast across a broad range of debilitating inflammatory diseases."

Hugs and best of luck!!
mig


Last edited by mig; 09/26/08 05:18 PM.